Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies
{{output}}
Median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has reached up to 30months in recent clinical trials of first line therapies. Following disease progression after the standard in both, 1st and 2nd line, combination chemotherapy... ...
